Omnihealth Practice

ONCOLOGY

Expanding first-line renal cell carcinoma treatment to patients with favorable risks: A sharing of local cases

01 Jun 2021

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

28 Feb 2021

Clinical challenges and considerations in managing HR+/HER2- advanced breast cancer in the post-CDK inhibitor setting

31 Dec 2020

A case of patient with advanced hepatocellular carcinoma - maximizing clinical benefits through timely switching away from failing regimen

31 Dec 2020

Denosumab as a well-tolerated and effective bone targeting treatment option for multiple myeloma patients with osteolytic lesions

31 Dec 2020

Brentuximab vedotin serves as a viable option to combine with chemotherapy for advanced stage Hodgkin lymphoma

31 Dec 2020

Bruton’s tyrosine kinase inhibitors delay disease progression and extend survival in patients with relapsed/refractory mantle cell lymphoma

30 Dec 2020

Enzalutamide improves overall survival and delays metastasis in patients with nonmetastatic, castration-resistant prostate cancer: A local case review

22 Nov 2020

The use of daratumumab in multiple myeloma: Developing novel immunotherapy strategies to prolong survival

31 Aug 2020

First-line treatment with immunotherapy in metastatic squamous NSCLC

31 Aug 2020

WCLC 2020

January 28-31, 2021 |

Virtual

Real-world analysis found ixazomib triple therapy effective in the management of relapsed/refractory multiple myeloma

HEMATOLOGY ONCOLOGY

28 Feb 2021

Professor Graham Jackson

Professor of Clinical Hematology,
Freeman Hospital,
The Newcastle Upon Tyne Hospitals,
NHS Foundation Trust, United Kingdom

Clinical challenges and considerations in managing HR+/HER2- advanced breast cancer in the post-CDK inhibitor setting

Demonstrating efficacy with a nearly doubled progression-free survival (PFS) rate, cyclin-dependent kinase inhibitor (CDKi) plus endocrine therapy (ET) have now become the new standard-of-care (SOC) in the first-line treatment setting of hormone receptor positive (HR+), human epidermal growth factor

31 Dec 2020

Dr. Chan, Wing-Lok Wendy

Clinical Assistant Professor,
Department of Clinical Oncology,
Li Ka Shing Faculty of Medicine,
The University of Hong Kong

SPINDLIN1 antagonist: An emerging cancer drug class?

Transcription factor has long been an attractive drug candidate for cancer drug development as it can potentially inhibit lineage-specific transcription.1,2 Recently, researchers from the University of Hong Kong reported a stable protein complex, Spindlin1, which binds stably to methylated histone a

09 Apr 2021

IG-IMRT as a more favorable adjuvant radiation alternative for hysterectomized cervical cancer patients

Radiotherapy as adjuvant treatment after total hysterectomy has proven to be effective in lowering cancer-specific mortality rate.1 However, traditional three-dimensional conformal radiotherapy (3D-CRT) as adjuvant treatment after total hysterectomy is associated with a series of late gastrointestin

31 Dec 2020

ONCOLOGY

Potential risk factors for developing nerve damage after cancer treatment

12 May 2021

Interview with the Expert: Dr. Peter YM Woo - Glioblastoma Multiforme (GBM) Treatment with Combination of TTFields and Chemotherapy: When and Where to Implement TTFields in the Clinical Setting?

Currently, the standard of care for patients with glioblastoma multiforme (GBM) consists of surgical resection or biopsy followed by adjuvant concurrent chemo-radiotherapy (CCRT) with temozolomide.1 To further improve the clinical course of GBM patients, tumor-treating fields (TTFields) were intr

07 Jun 2021

Dr. Peter YM Woo

Specialist in Neurosurgery